Lerdelimumab

Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research[1][2].

Product Specifications

CAS Number

[285985-06-0]

Product Name Alternative

CAT-152

UNSPSC

12352203

Target

TGF-beta/Smad

Type

Inhibitory Antibodies

Related Pathways

Stem Cell/Wnt; TGF-beta/Smad

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/lerdelimumab.html

Purity

97.27

Solubility

10 mM in DMSO

Smiles

[Lerdelimumab]

References & Citations

[1]Mead AL, et al. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003 Aug;44 (8) :3394-401.|[2]Wormstone IM, et al. TGF-beta2-induced matrix modification and cell transdifferentiation in the human lens capsular bag. Invest Ophthalmol Vis Sci.